Published: 2021-09-27

Effect of coffee in prevention of non-alcoholic fatty liver disease

Anuj Gupta, Joshika Agarwal, Rajni Gupta


Background: Non-alcoholic fatty liver disease which is also known as metabolic associated fatty liver disease is characterized by accumulation of fat in liver without any underlying clear etiology such as chronic alcohol abuse. Our study aimed to evaluate the effect of coffee in prevention of non-alcoholic fatty liver disease and its effect on various biochemicals like lipids, ESR, CRP, ferritin etc.

Methods: We conducted a retrospective study in a tertiary care public sector hospital. The study was conducted among 300 patients. 150 had confirmed diagnosis of NAFLD through ultrasound abdomen and 150 had normal liver on ultrasound abdomen. Both study groups were asked to fill a predetermined questionnaire which included questions on amount of coffee and other caffeinated beverages, physical activity, and demographic data. P value of less than 0.05 was considered significant.

Results: Study compared the effect of coffee on prevention of non-alcoholic fatty liver disease (NAFLD). We found that subjects who did not drink coffee had more odds of developing NAFLD as compared to those who did. Inflammatory markers and lipid profile were found to be lower in those who drank coffee as compared to those who did not.

Conclusions: Based on multiple studies done on mice and rat at molecular level and our study, we conclude that various components present in coffee play a significant role in preventing NAFLD, liver fibrosis and even liver cancer. Coffee has also shown to have anti-inflammatory properties and lowers lipid level in blood.


Coffee, Fatty liver, Liver fibrosis, NAFLD

Full Text:



Eslam M, Sanyal AJ, George J, an international consensus panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999-2014.e1.

Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. (January 2018). The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-57.

Wong VW, Chan WK, Chitturi S, Chawla Y, Dan YY, Duseja A, et al. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment. J Gastroenterol Hepatol. 2018;33(1):70-85.

Iser D, Ryan M. Fatty liver disease- a practical guide for GPs. Austral Fam Phys. 2013;42(7):444-7.

Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84.

Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology. 2020;158(7):1851-64.

Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-57.

Golabi P, Paik J, Hwang JP, Wang S, Lee HM, Younossi ZM. Prevalence and outcomes of non-alcoholic fatty liver disease (NAFLD) among Asian American adults in the United States. Liver Int. 2019;39(4):748-57.

Ma Y, Gao M, Liu, D. Chlorogenic acid improves high fat diet-induced hepatic steatosis and insulin resistance in mice. Pharm Res. 2015;32(4):1200-9.

Wang H, Guan W, Yang W, Wang Q, Zhao H, Yang F, et al. Caffeine inhibits the activation of hepatic stellate cells induced by acetaldehyde via adenosine A2A receptor mediated by the cAMP/PKA/SRC/ERK1/2/P38 MAPK signal pathway. PLoS One. 2014;9(3).

Hirakawa N, Okauchi R, Miura Y, Yagasaki K. Antiinvasive activity of niacin and trigonelline against cancer cells. Biosci Biotechnol Biochem. 2005;69:653-8.

Bøhn SK, Blomhoff R, Paur I. Coffee and cancer risk, epidemiological evidence, and molecular mechanisms. Mol Nutr Food Res. 2014;58(5):915-30.

Paur I, Balstad TR, Blomhoff R. Degree of roasting is the main determinant of the effects of coffee on NF-kappaB and EpRE. Free Rad Biol Med. 2010;48:1218-27.

Vitaglione P, Morisco F, Mazzone G, Amoruso DC, Ribecco MT, Romano A, et al. Coffee reduces liver damage in a rat model of steatohepatitis: the underlying mechanisms and the role of polyphenols and melanoidins. Hepatology. 2010;52(5):1652-61.

Tajik N, Tajik M, Mack I, Enck P. (2017). CGA has both antioxidant and anti-infammatory potential; it therefore seems conceivable that the positive effects observed after decaffeinated coffee ingestion might be due to CGA, the main phenolic components in coffee, on health: a comprehensive review. Eur J Nutr. 2017;56(7):2215-44.

Velázquez AM, Roglans N, Bentanachs R, Gené M, Sala-Vila A, Lázaro I, et al. Effects of a low dose of caffeine alone or as part of a green coffee extract, in a rat dietary model of lean non-alcoholic fatty liver disease without inflammation. Nutrients. 2020;12(11):1-19.

Sato Y, Itagaki S, Kurokawa T, Ogura J, Kobayashi M, Hirano T, et al. In vitro and in vivo antioxidant properties of chlorogenic acid and caffeic acid. Int J Pharm. 2011;403(1-2):136-8.

Xu M, Yang L, Zhu Y, Liao M, Chu L, Li X, et al. Collaborative effects of chlorogenic acid and caffeine on lipid metabolism via the AMPKα-LXRα/SREBP-1c pathway in high-fat diet-induced obese mice. Food Funct. 2019;10:7489-97.

Ding WX. (2014). Drinking coffee burns hepatic fat by inducing lipophagy coupled with mitochondrial β-oxidation. Hepatology. 2014;59(4):1235-8.

Choi EY, Jang JY, Cho YO. (2010). Coffee intake can promote activity of antioxidant enzymes with increasing MDA level and decreasing HDL-cholesterol in physically trained rats. Nutr Res Pract. 2010;4(4):283-9.

Shimoda H, Seki E, Aitani M. Inhibitory effect of green coffee bean extract on fat accumulation and body weight gain in mice. BMC Complement. Altern Med. 2006;6:9.

Ray K. (2013). Liver: caffeine is a potent stimulator of autophagy to reduce hepatic lipid content- a coffee for NAFLD? Nat rev Gastroenterol Hepatol. 2013;10(10)563.

Gelatti U, Covolo L, Franceschini M, Pirali F, Tagger A, Ribero ML, et al. Coffee consumption reduces the risk of hepatocellular carcinoma independently of its aetiology: a case-control study. J Hepatol. 2005;4:528-34.

Bravi F, Boscetti C, Tavani A, Bagnardi V, Gallus S, Negri E, et al. Coffee drinking and hepatocellular carcinoma risk: a meta-analysis. Hepatology. 2007;46:430-5.

Larsson SC, Wolk A. Coffee consumption and risk of liver cancer: a meta-analysis. Gastroenterology. 2007;132:1740-5.